Indivior Pharmaceuticals, Inc. (INDV) Stock Analysis
Breakout setup
Healthcare · Drug Manufacturers - Specialty & Generic
Hold if already holding. Not a fresh buy at $38.13, but acceptable to hold if already in. Reason: mixed signals — some dimensions strong, others weak.
Indivior Pharmaceuticals is the market leader in long-acting injectable medications for opioid use disorder, with SUBLOCADE (monthly buprenorphine injection) and SUBOXONE Film as its core products, sold primarily in the US which accounted for 85% of net revenues in 2025.... Read more
Hold if already holding. Not a fresh buy at $38.13, but acceptable to hold if already in. Reason: mixed signals — some dimensions strong, others weak. Chart setup: Golden cross, above all MAs, RSI 53, MACD bullish. Maintain position. Not compelling to add more. Score 6.6/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 56d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-06-11Recent Developments — Indivior Pharmaceuticals, Inc.
Latest news
- NEWS A Look at Indivior Pharmaceuticals Inc (INDV) After 3.6% Gain -- GF Value $21.89 vs Price $33.39 - GuruFocus — GuruFocus positive
- NEWS INDV Insider Filing: Barry Patrick A Restricted Stock Units, April 28, 2026 - Meyka — Meyka neutral
- NEWS INDV Insider Trading: Barry Patrick Restricted Stock Units Filing April 21, 2026 - Meyka — Meyka neutral
- NEWS Indivior Pharmaceuticals Inc. (INDV) Q1 earnings and revenues beat estimates - MSN — MSN positive
- NEWS Indivior Pharmaceuticals Inc. (INDV) Q1 Earnings and Revenues Beat Estimates - Yahoo Finance UK — Yahoo Finance UK positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 ceiling hit
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $38.13, but acceptable to hold if already in. Reason: mixed signals — some dimensions strong, others weak. Chart setup: Golden cross, above all MAs, RSI 53, MACD bullish. Maintain position. Not compelling to add more. Target $44.80 (+17.5%), stop $35.46 (−7.5%), A.R:R 1.2:1. Score 6.6/10, moderate confidence.
Take-profit target: $44.80 (+17.5% upside). Target $44.80 (+17.5%), stop $35.46 (−7.5%), A.R:R 1.2:1. Stop-loss: $35.46.
Indivior Pharmaceuticals, Inc. trades at a P/E of 19.5 (forward 9.7). TrendMatrix value score: 8.0/10. Verdict: Hold.
12 analysts cover INDV with a consensus score of 4.3/5. Average price target: $52.
What does Indivior Pharmaceuticals, Inc. do?Indivior Pharmaceuticals is the market leader in long-acting injectable medications for opioid use disorder, with...
Indivior Pharmaceuticals is the market leader in long-acting injectable medications for opioid use disorder, with SUBLOCADE (monthly buprenorphine injection) and SUBOXONE Film as its core products, sold primarily in the US which accounted for 85% of net revenues in 2025. SUBLOCADE represented 69% of total net revenues in 2025, up from 64% in 2024. The company redomiciled from the UK to the US in January 2026.